Advancements
in medicine have led us to a time where there are options available to
regenerate organs. Stem cell surgery is the use of stem cells to treat ailments
and is gaining popularity for its ability to regenerate body tissue. Healthcare
market research report consulting shows that it already has wide ranged
uses in orthopedics, blood cell formation and brain and spinal cord injuries.
Its application on the heart is also being extensively researched. Heart
failure occurs when the heart does not pump sufficient blood to maintain bodily
functions.
Heart
Failure is a chronic disease needing lifelong management however, with
treatment signs and symptoms can improve even making the heart stronger
sometimes thereby helping you live longer and reducing your chance of dying
suddenly. Doctors can sometimes correct heart failure by treating the
underlying cause for example repairing a heart valve or controlling a fast
heart rhythm may reverse heart failure. For most people though, treatment of
heart failure involves a balance of the right medications and in some cases use
of devices that help the heart beat and contract properly. Now a new research
is being carried out to augment the use of stem cells in the process of
treatment. Clinical trial planning is
underway at US based MedStar Heart & Vascular Institute to determine
whether novel stem cell therapy will improve heart function for patients with
heart failure. The trial will use CardioCell’s proprietary Mesenchymal Stem
Cells (MSCs) manufactured by Stemedica. The goal is to improve outcomes in
patients with heart failure and left ventricular assist devices (LVADs).
This
research is a leap forward not only from the medical science perspective but
also from a business standpoint. Healthcare
business review indicates that the global stem cell market is expected
to reach nearly USD 16 billion by 2025 growing at a CAGR of 9.4% approximately.
This research has led to the partnership of three highly reputed US based
institutions. MedStar Heart &
Vascular Institute is a national leader in research, diagnosis and treatment of
cardiovascular disease and has been consistently ranked as one of the premier
destinations for cardiac care in the region for more than 55 years. Stemedica
Cell Technologies is a global leader in regenerative medicine that develops,
manufactures and distributes adult allogeneic stem cell products and houses
more than 30 years of research and innovation. CardioCell is a global
biotechnology company that explores therapeutic applications of stem cells and
has an exclusive worldwide license from Stemedica Cell Technologies for the
exploration of therapeutic cardiovascular indications including Chronic Heart
Failure (CHF).
This
research also proves that stem cells are gaining global interests. Stem cells
are being used as building blocks for humans that are not only benefiting
medical science by increasing its scope but also paving the way for further
research and discoveries. Big medical companies are actively investing in the
bright future of stem cells and this is evident by the research project being
carried out by MedStar Heart & Vascular Institute. Technologically advanced
countries are constantly attempting to increase the utility from stem cell
products which is the main growth driver with the US being at the forefront of
this movement.
To know more, click on the link below:
Related
Report:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment